| Abstract | Statements produced by the Regulatory Authorities have impacted significantly on the practice of Menopausal Medicine. The advice that the lowest dose of hormone therapy should be given for the shortest possible time and that hormone therapy should no longer be a first-line treatment for osteoporosis has lead to a major shift in prescribing practice. Since these statements have such an enormous impact, this presentation will consider further the background to the authorities and the mechanism by which their decisions were reached. |
| Authors | M A Lumsden
(Affiliation: Department of Reproductive and Maternal Medicine, Glasgow Royal Infirmary, Glasgow, UK.)
|
| Journal | Climacteric : the journal of the International Menopause Society
(Climacteric)
Vol. 10 Suppl 2
Pg. 121-4
(Oct 2007)
ISSN: 1369-7137 United States |
| PMID | 17882687
(Publication Type: Journal Article)
|
| Topics |
- Dose-Response Relationship, Drug
- Drug Monitoring
(methods)
- Estrogen Replacement Therapy
(adverse effects, trends)
- Europe
- Female
- Great Britain
- Health Education
(organization & administration)
- Humans
- Legislation, Drug
- Practice Guidelines as Topic
- Public Opinion
- Randomized Controlled Trials as Topic
- United States
- Women's Health
|
